Elasticity Imaging for Breast Cancer
Trial Summary
What is the purpose of this trial?
For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Harmonic Motion Imaging for breast cancer?
Research shows that Harmonic Motion Imaging (HMI) can help differentiate between benign and malignant breast tumors by measuring how much the tissue moves when sound waves are applied. Malignant tumors tend to move less than benign ones, which can help doctors identify cancerous tissue without needing a biopsy.12345
Is elasticity imaging for breast cancer safe for humans?
The research on harmonic motion imaging (HMI) for breast cancer suggests it is a non-invasive technique that uses sound waves to assess tissue stiffness, and it has been tested in human subjects without reported safety issues. Additionally, ultrasound elastography, a related technique, is widely used and considered safe for evaluating tissue properties in various conditions.13678
How does elasticity imaging differ from other breast cancer treatments?
Elasticity imaging is unique because it uses ultrasound to assess the stiffness of breast tissue, helping to differentiate between benign and malignant tumors without invasive procedures. This technique provides a non-invasive way to evaluate the mechanical properties of breast tissue, potentially reducing the need for unnecessary biopsies.125910
Research Team
Elisa Konofagou, PhD
Principal Investigator
Columbia University
Eligibility Criteria
This trial is for women aged 18 or older with invasive breast cancer of at least 4 mm in size, who are eligible for neoadjuvant systemic therapy. It's not suitable for pregnant or breastfeeding women, those with breast implants, or a history of laser/radiation therapy to the affected breast.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive neoadjuvant chemotherapy and undergo Harmonic Motion Imaging (HMI) to predict response
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Harmonic motion imaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator